Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: The main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-α. Results of the CML89 trial of the Spanish collaborative group on interferon-α2a and CML

Haematologica

Volumn 84, Issue 11, 1999, Pages 978-987

  Steegmann, Juan Luis ^a   Odriozola, Jesús ^b   Rodriguez Salvanés, Francisco ^a   Giraldo, Pilar ^c   García Laraña, José ^b   Ferro, María Teresa ^b   Benítez, Esmeralda ^c   Pérez Pons, Concepción ^d   Giralt, Manuel ^c   Escribano, Luis ^b   Lavilla, Esperanza ^j   Miguel, Amparo ^j   Areal, Carlos ^e   Pérez Encinas, Manuel ^f   Abad, Ana ^g   Maldonado, Juan ^h   Massagué, Isabel ⁱ   Fernández Rañada, José M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Hospital Ramón y Cajal   (Italy)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e Universidad de La Coruña   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL MARINA ALTA   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j Hospital de la Princess ^*

more..

Author keywords

Basophils; Chronic myeloid leukemia; Cytogenetic response; Interferon ; Prognosis

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON;

ARTICLE; BASOPHIL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROGNOSIS; SURVIVAL; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; BASOPHILS; CHILD; CYTOGENETIC ANALYSIS; FEMALE; HEMATOLOGIC TESTS; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PROGNOSIS; SPAIN; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032737579     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologie remission and cytogenetic improvement induced by recombinant human interferon-α in chronic myelogenous leukemia. N Engl J Med 1986; 314:1065-9.
2. Giralt S, Kantarjian H, Talpaz M. The natural history of chronic myelogenous leukemia in the interferon era. Semin Hematol 1995; 32:152-8.
3. Kantarjian HM, Smith T, O'Brien S, et al. Prognostic factors for response and survival with alpha-interferon (IFN-α) therapy in early chronic phase chronic myelogenous leukemia (CML) [abstract]. Blood 1993; 82 (suppl 1):378a.
4. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114:532-8.
5. Talpaz M, Trujillo JM, Hittelman WN, Keating MJ, Gutterman JU. Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon. Br J Haematol 1985; 60:619-24.
6. Egert G, Kanz L, Lohr GW, Fauser AA. Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia with interferon alpha. Blut 1990; 60:282-6.
7. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998; 16:1526-31.
8. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-5.
9. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised, multicentre trial of interferon-α1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345:1392-7.
10. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84:4064-77.
11. The Benelux CML Study Group. Randomized study on hydroxyurea versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia. Blood 1998; 91:2713-21.
12. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92:1541-8.
13. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122:254-61.
14. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906-16.
15. Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993; 82:2975-84.
16. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990; 88:1-8.
17. Steegmann JL, Requena MJ, Casado LF, et al. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha). Am J Hematol 1996; 53:169-74.
18. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63:789-99.
19. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
20. Parmar MKB, Machin D. Survival analysis: A practical approach. Chichester: John Wiley Sons, 1995.
21. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1:710-9.
22. Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med 1996; 15:2797-812.
23. Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 34:187-220.
24. Thaler J, Gastl G, Fluckinger T, et al. Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group. Ann Hematol 1996; 72:349-55.
25. Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R. The M.D. Anderson Cancer Center experience with interferon-α therapy in chronic myelogenous leukemia. Bailliére Clin Haematol 1997; 10:291-305.
26. Mahon FX, Faberes C, Montastruc M, et al. High response rate using recombinant interferon-α in patients with newly diagnosed chronic myeloid leukemia. Bone Marrow Transplant 1996; 17(Suppl 3): S33-7.
27. O'Brien S, Kantarjian H, Talpaz M. Practical guidelines for the management of chronic myelogenous leukemia with interferon α. Leuk Lymphoma 1996; 23:247-52.
28. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune mediated and unusual complications during IFN-α therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401-7.
29. Steegmann JL, Pinilla I, Requena MJ, et al. The direct antiglobulin test is frequently positive in chronic myeloid leukemia patients treated with interferon-α. Transfusion 1997; 37:446-7.
30. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69:1280-8.
31. Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66:1326-35.
32. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon-α. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850-8.
33. Bosma TJ, Kennedy MA, Bodger MP, Hollings PE, Fitzgerald PH. Basophils exhibit rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 1988; 2:141-3.
34. Fishman P, Sredni B, Djaldetti M. The relationship between interleukin-3-like activity and basophil production in chronic myeloid leukemia patients. Immunol Lett 1991; 28:73-7.
35. Denburg JA, Wilson WE, Bienenstock J. Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukemia. Blood 1982; 60:113-20.
36. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon-α. J Natl Cancer Inst 1998; 90:850-8.
37. Carella AM, Frassoni F, Melo J, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82:478-95.